Avidity Biosciences Inc
RNA
View Detailed Chart
46.580USD
-2.000-4.12%
Close 08/29, 16:00（ET）Quotes delayed by 15 min
5.63BMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-4.12%
5 Days
+0.50%
1 Month
+26.30%
6 Months
+52.02%
Year to Date
+60.18%
1 Year
+5.86%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated：2025-08-29Key Insights
The company's fundamentals are relatively weak.Its valuation is considered fairly valued,and institutional recognition is very high.Over the past 30 days, multiple analysts have rated the company as a Buy.Despite a very weak stock market performance, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analysts' Target
Based on
18
analysts
Buy
Current Rating
67.412
Target Price
+44.72%
Upside Space
Disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Avidity Biosciences, Inc. is a biopharmaceutical company. The Company is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). The AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Its advancing and expanding pipeline has three programs in clinical development. AOC 1001 is designed to treat people with myotonic dystrophy type 1 (DM1) and is in phase I/II development with the ongoing MARINA open label extension study (MARINA-OLE). AOC 1044 is designed for people with Duchenne muscular dystrophy and is in phase I/II development with the EXPLORE44 trial. AOC 1020 is designed to treat people living with facioscapulohumeral muscular dystrophy (FSHD) and is in Phase I/II development with the FORTITUDE trial.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 18.14% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 10.90M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 85.24.
Undervalued
The company’s latest PE is -13.09, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 141.72M shares, decreasing 2.35% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 10.67M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.95.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
Avidity Biosciences, Inc. is a biopharmaceutical company. The Company is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). The AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Its advancing and expanding pipeline has three programs in clinical development. AOC 1001 is designed to treat people with myotonic dystrophy type 1 (DM1) and is in phase I/II development with the ongoing MARINA open label extension study (MARINA-OLE). AOC 1044 is designed for people with Duchenne muscular dystrophy and is in phase I/II development with the EXPLORE44 trial. AOC 1020 is designed to treat people living with facioscapulohumeral muscular dystrophy (FSHD) and is in Phase I/II development with the FORTITUDE trial.
Ticker SymbolRNA
CompanyAvidity Biosciences Inc
CEOMs. Sarah Boyce
Websitehttps://www.aviditybiosciences.com/
Related Instruments
+0.08%
+1.00%
+1.26%
-0.11%
+0.02%
+1.09%
+0.64%
+0.74%
+0.63%
+0.36%
-0.92%
-0.26%
+0.68%
+1.19%
+0.88%
+0.56%
+0.03%
+1.06%
+0.19%
-1.29%
